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When mice receiving  a  tumor homograft are pre~injected  with killed tumor 
tissue, or with non-living  preparations of certain normal tissues from the strain 
to which the tumor is indigenous,  the growth of the tumor is often markedly 
enhanced.  In tumor-host combinations favorable to the phenomenon,  all,  or 
almost all,  pretreated mice die with progressively growing  tumor and all un- 
treated controls survive. The effect is surprising  in that the pretreatmeut em- 
ploys a  schedule that would be expected to immunize and hence to diminish 
rather than to promote tumor growth. 
This phenomenon has been variously called the XYZ effect,  the enhancing 
effect, and immunological  enhancement. Reviews have been written by Casey 
(1), by Snell and coworkers (2, 3) and by Kaliss (4). Only a few salient facts are 
mentioned here, with discussion  deferred to the end of the paper. 
An important step in the elucidation of the enhancing phenomenon was taken 
by Kaliss and coworkers when they showed that the enhancing effect can be 
passively transferred with the serum of pretreated mice. The evidence proves 
that antibodies directed against the isoantigens of the tumor are an essential 
factor in the phenomenon (5, 6, 4), and Kaliss now defines enhancement as the 
progressive growth of homografts, produced by specific antiserum. This is prob- 
ably good usage; it limits the term to a clear effect and an experimentally well 
defined cause. It is worth emphasizing  that in suitable tumor-host systems, pro- 
gressive tumor growth in mice injected intrapefitoueally with a hyperimmune 
antiserum is even more consistent than in mice enhanced by the pre-injection of 
freeze-dried  tumor. 
Another major advance, important in understanding not only the enhancing 
effect but also the homograft reaction in general,  was the demonstration by 
Kidd (7) and later by Mitchison (8)  that the major agent in the rejection of 
most .grafts is the immune lymph node cell. Mitchison showed that homograft 
immunity can be "adoptively transferred" by the intraperitoneal  injection of 
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minced lymph nodes from the area draining a tumor transplant.  Evidence from 
various sources indicates that the lymphocyte does not act by releasing  anti- 
body into the circulation,  but rather migrates to and directly attacks the graft 
(3). Grafts of leukemic or normal lymphoid tissues present a special case; these, 
with a few possible exceptions,  can be destroyed by humoral antibody and com- 
plement (9). It follows as a corollary that leukemias cannot be enhanced. 
One other fact is essential  for understanding the enhancing  effect. Injections 
of killed tissue produce only, or predominantly, humoral antibody, whereas in- 
jections of living  tissue tend to produce both cellular  and humoral immunity 
(3). A close parallel to this difference in effect of living and dead tissue is pro- 
vided by bacteriological studies.  Holland and  Pickett  (10)  have found  that 
whereas Br~ella-infected guinea pigs show both a high antibody titer and de- 
layed skin reactions,  animals  vaccinated with heat-killed organisms produce 
antibody but do not develop delayed hypersensitivity. 
In the light of these facts, two hypotheses to account for the enhancing  effect 
can now be considered. 
Hypothesis  1.--Kaliss  (4) interprets enhancement as "due to some 'physio- 
logical'  alteration in the tumor, induced by its contact with antiserum, which 
insures its survival despite the hostile responses  of the host." Kaliss considers, 
and rejects, a variant of this hypothesis; namely, that  the effect of the antise- 
rum is to modify the tumor through "immunological selection." We agree that 
this is not a major factor in the enhancing  phenomenon. 
Hypothesis 2.--A second and entirely different mechanism has been suggested 
by Snell (11, 3) and independently by Billingham,  Brent, and Medawar (12). 
Briefly, it is postulated that the effect of the antiserum is in some way to block 
the development of the cellular type of immunity in the nodes and other lymph- 
oid tissues draining the graft. Since the destruction of grafts, other than leuke- 
mias,  is dependent on such cellular  immunity,  a  blockage of this sort would 
permit the graft to grow. Billingham  et al. have referred to the postulated effect 
as  an  " 'afferent inhibition'  of transplantation  immunity,"  and  Snell  as  "a 
'walling off' of the graft by circulating antibody, so that antigens either do not 
reach the regional nodes, or reach them in an inactive state." 
This paper reports tests of these two hypotheses. 
To  avoid circumlocution,  mice with circulating  isoanfibody as a  result of 
freeze-dried  tissue injections will be called  actively enhanced mice,  and mice 
which have received antibody by transfer  will be called  passively enhanced 
mice. 
Materials  and Methods 
M/ce.--The mice used in tests of hypothesis 1 were mostly from two strains, A/WySn 
and B10.D2  (abbreviated to B.D. in Fig. 2).  The latter is a subline of C57BL/10 in which 
H-2  d has been substituted for H-2  ~ (13). For reasons not fully understood, strain A tumors are 
more easily enhanced in strain B10.D2 than in strain C57BL/10. A few tests were also made G. D. SNELL, H. ~'. WlNN, J. H. STIMPI~LING, AND S. jr. PARKER  295 
with strains  A.SW (13),  C57BL/10ScSn,  and  C3H/DiSn.  All mice were born in the same 
month,  and  the youngest were 7~  weeks old when enhancing injections were started.  All 
experimental groups contained equal numbers of males and females. 
In most experiments testing hypothesis 2, strains A/WySn and B10.D2 were again em- 
ployed. In one instance C57BL/Ks  (also an  H-2  J subline)  was  substituted  for B10.D2.  A 
few lymph node assays were performed in the hybrid (A X  B10.D2)F1.  In all parts of experi- 
ments in which an immune response was being studied, mice were at least 8 weeks old. Mice 
in any one experiment were matched as to sex and age. 
Tumor.--The tumor used was SaI (also called Sarcoma I), native to strain A. 
In tests of hypothesis 1, the subline of SaI employed was kindly provided by Dr. Kaliss. 
All experimental mice were implanted subcutaneously in the right axilla by trocar.  Tumors 
were palpated weekly and a record of tumor size made in the form of a drawing. 
In tests of hypothesis 2, the Snell subllne of the ascltes form of the tumor (called SaI-A), 
was used. Whereas the Kaliss subline grew progressively in about 50 per cent of untreated 
B 10.D2 hosts, the Snell subllne rarely grew progressively in such animals. To prevent dotting, 
heparln from a  stock  solution (10  rag.  heparin in 10 ml. of 0.93 per cent saline)  was added 
to the aseltes fluid in the proportion 1 in 10 to 1 in 20. 
Aaive Enhonc~.--Actlvely  enhanced B10.D2's were used in tests of hypothesis 1. The 
tissue used for enhancement was lyophllized A spleen. The enhancing treatment consisted of 
5 intraperitoneal injections of 5 nag. each over a 2 week period, with tumor given 14 days after 
the last injection. 
Pas.vive Enhanc~ne',,a.--In  tests of hypothesis 2, passive enhancement was used. The anti- 
serum employed was hyperimmune B10.D2 anti-A. Multiple injections of living SaI, some- 
times preceded by an injection of normal or SaI tissue  extract, were  used  for  imunization. 
Mice were sometimes bled four times, with a booster injection of SaI after the second bleeding. 
The antiserum was stored in a deep-freeze. Mice to be enhanced were given an intraperitoneal 
injection of antiserum, usus~Lly about an hour before, but in certain specified  cases,  a day or 
more after, the subcutaneous implantation of SaI or strain A normal tissue. Except as other- 
wise specified,  the dose per mouse was 0.3 ml. 
Tumor and Tissue Inje,  aions.--The blocking effect of antiserum was tested not only against 
tumor SaI-A, but also against normal tissues. When tumor was used, ascites fluid was drawn 
from the peritoneal cavity, a cell count made, and the desired dilution prepared. The normal 
tissues employed were embryo, thymus (from 3- to 5-week-old mice), lymph nodes and spleen. 
Embryos  near term were prepared  as a  mince and  injected  by  trocar.  Other  tissues  were 
usually prepared as a cell suspension in the cytosieve (14), and diluted to the appropriate cell 
count. In certain instances tissues were minced with scissors  and mixed with the tumor. 
The medium used for preparing cell suspensions was a  buffered glucose-Ringer's solution 
(hereafter referred to as BGR). This was made as previously described (14)  except that we 
now use a phosphate instead of a citrate buffer. 
Injections of tumor or tissue for testing the effect of enhancement usually were made sub- 
cutaneously, either on both flanks or on the right flank only. Entry near a draining node was 
avoided in the case of tumor. 
Red Cell Agglutination  Tests.--The method used  was the serum-dextran technique of Corer 
and  Mikulska  (15). 
Lymph Node Assay.--To obtain a  critical test of hypothesis 2, an assay for the level of 
cellular immunity in  the various lymphoid organs is essential.  While the  method used  by 
Mitchison in earlier studies in this laboratory  (8)  to demonstrate cellular immunity might 
serve, it is neither sensitive nor quantitative. An assay recently developed by Winn (9)  re- 
quires only about 0.01 to 0.03 as much lymphoid tissue as the earlier method, and, because of 
this greater sensitivity, allows quantitative determinations. 296  DEPRESSION  OF rMMUNE  RESPONSE  TO IIOMOGRA]?TS 
The general procedure is shown in Fig. 1. A cell suspension from the nodes or spleens to be 
assayed is prepared in the cytosieve (14), a  cell count made, and serial dilutions prepared. 
A known number of ascites tumor calls is mixed with each dilution, and the mixture injected 
at once into appropriate mice. A week or more later the mice are killed and the tumors weighed. 
Absence of growth, or a significant reduction of growth as compared with controls, is indica- 
tive of immunity. For the assay, either the original tumor-donating strain, the original host 
strain, or an F~ hybrid between the two can be employed. Experience has shown that the use 
of the original host strain (strain B10.D2 in Fig.  1) gives the most sensitive results. This is 
because the nodes to be assayed and the assay animals are mutually compatible; the animals 
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FzO. 1. Diagram showing the method of lymph node assay. 
do not react against and destroy the node cells, and the cells are not diverted from the antigens 
of the tumor by corresponding antigens in the host. The details of the technique are as follows. 
The nodes used were the axiilary, brachial, and inguinal. These were taken from one or 
both sides according as stimulation was on one or both sides. The typical experimental group 
consisted of the nodes from 10 mice. These were collected in chilled BGR, placed in a cytosieve, 
BGR added (usually 4 ml.), and a call suspension prepared. A cell count was then made, serial 
dilutions prepared  (usually),  SaI-A added,  and each mixture injected at once in the right 
axilla of 10 mice. 
In order that the results of different experiments might be easily compared, the dilutions 
were usually a standard series such that each mouse received one of the following numbers of 
lymph node cells: 8, 4, 2, 1, 0.5, or 0.25 million. When the cellular immunity was likely to be 
low, in addition to the specified dilutions, one group received undiluted node cell suspension 
mixed with tumor. G. D. SNELL, H. J. WINN', J. H. STIMPFLING,  AND S..]'. PARKER  297 
For assay in strain A, each mouse received lymph node cells mixed with 5,000 cells SaI-A; 
for assay in (A X  B10.D2)FI or in B10.D2, with  1,000,000 cells SaI-A, usually in 0.2 cc. 
Tumors were removed and weighed after an appropriate  interval. 
In a few early experiments, the medium used was chilled BGR plus normal serum, but later 
chilled BGR only was used. The McCartney bottles containing the cell suspensions were kept 
on ice or in the refrigerator at all times. 
Plan for the Test of Hypothesis/.--The basic plan for the test of hypothesis 1 
was to compare the growth in B10.D2 mice of SaI from two sources, A's and 
enhanced B10.D2's.  If the effect of the enhancing  treatment  is  to modify the 
tumor so that it can resist the hostile responses of the host, this should show up 
in faster or better growth of the tumor from the second of the two sources. 
Four A's (with the tumor from two of them pooled) and 5 enhanced B10.D2's were used 
as donors, the tumor from each donor being passed to 10 or more untreated  B10.D2's. Mul- 
tiple donors were used to average out any subline variation of the tumor that might occur in 
a single donor simply as the result of chance. Tumor from 2 enhanced BI0.D2's,  ~740 and 
9 49, was also passed into A's and thence into untreated  B10.D2'S. This was done becaues 
one possible source of altered growth in B10.D2's of an A tumor taken from BI0.D2's is the 
absence of A lymphocytes and other A white blood cells. Such cells are usually abundantly 
present in an A tumor taken from A's, and since normal lymphoid cells are an excellent agent 
for inducing homograft immunity (3), an  A tumor homografted from A's might on this ac- 
count alone be rejected more rapidly than an A tumor homografted from B10.D2's. 
Tumors were also passed from an enhanced BI0.D2, o~45, and from an A, 9 64, to groups 
of A.SW, C3H and C57BL/10. 
RESULTS 
Results of the Test of Hypothesis/.--The  results are shown in Fig. 2. A  con- 
trol  group of 25  enhanced B10.D2's  all  succumbed  to  the  tumor.  Of 50 un- 
treated B10.D2's receiving SaI directly from A's, 24, or 48 per cent, succumbed. 
The corresponding figure for untreated B10.D2's receiving tumor v/a enhanced 
B10.D2's was 22 out of 50, or 44 per cent, and for untreated B10.D2's receiving 
tumor which had passed in succession through enhanced B10.D2's and A's, 12 
out of 28, or 43 per cent. It is evident that there was no demonstrable difference 
in the fraction dying as a  result of the different types of passage.  Residence in 
enhanced B10.D2's did not modify the tumor so that it  grew better in other, 
unenhanced B10.D2's. Neither was there any improved growth of such tumors 
when passed to other foreign strains. Tumor from an A mouse and tumor from 
an enhanced B10.D2, respectively, grew in 8 out of 10 and 7 out of 9 A.SW, in 
3 out of 5 and 0 out of 6 C3H, and in 0 out of 10 and 0 out of 10 C57BL/10. 
Neither was there any significant difference in the rate of growth of these tu- 
mors. 
While the average mortality from tumors taken from different types of donor 
was the same, there was considerable variation in tumors taken from individual 
donors. Thus tumor from enhanced Bi0.D2  ~34 killed  I  out of 10 untreated 
B10.D2's, while a  comparable passage from oz55 killed 8 out of 10. This illus- 
trates the importance of pooling the results from multiple donors. 298  DEPRESSION  OF IMMUNE  RESPONSE TO IIOMOGRAI~TS 
Test of Hypothesis 2: Blockage by Antiserum of Cellular Immunity.-- 
In one series of experiments, B10.D2 mice, some of which had and some of which had not 
received antibody, were immunized with various strain A tissues implanted subcutaneously on 
both sides, and the nodes assayed for immunity. The tissues used for immunization were SaI-A, 
thymus, and embryo. The assay was performed in (A X  B10.D2)FI's.  Mice of this genotype 
offer the advantage that SaI-A is compatible, so that any inhibition of its growth must be 
due entirely to immunity of the transferred  nodes, but the disadvantage that the node cells 
can react against the A component  in the assay hosts as well as against the tumor. The re- 
suits of these experiments are shown in Table I. 
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Fro. 2. Diagram showing the various passages of SaI used to test hypothesis 1. The result 
for each terminal group is given as a fraction in which the numerator is the number dying 
from the tumor and the denominator the total number inoculated. 
The  mean  tumor  weights  in  5  groups  of controls,  which  received normal 
B10.D2 node cells mixed with SaI-A, were 1.56, 0.57, 0.68, 0.74, and 0.63 gm. 
The group with a  mean weight of 1.56 was killed and weighed at 8  days, the 
others at 7 days. In some of the groups receiving the higher concentrations of 
presumptively immune  B10.D2  node  cells, weights  much  smaller than  these 
were found.  We have, somewhat arbitrarily, taken mean weights of 0.27 gm. or 
less as indicative of inhibition. The difference between  these weights and the 
controls is highly significant (P <  0.01). Using these values, we find that node 
cells from mice receiving tumor alone were active in doses of 1.5 million cells per 
mouse or greater, and inactive at doses of 0.75 million cells or less. Node cells of G. D.  SNELL,  H.  ~'. WIN'N, ~'. H.  STIMPI~LING, AND S.  J.  PARKER  299 
mice receiving tumor plus antiserum were inactive in all doses up to and in- 
cluding 12 million cells per mouse. The activity generated in the absence of an- 
tiserum is thus at least 16 times greater than the activity generated in its pres- 
ence. After immunization with thymus, node cells from unenhanced mice were 
active at the 4 million cell level and inactive at the 2 million cell level, whereas 
node cells from enhanced mice showed no activity at the maximum attainable 
dose,  10.5 million cells per mouse. There is not less than a  5-fold difference. A 
TABLE I 
Assay of Draining Lymph Nodes of BIO.D2 Mice Immunized with Various Strain A  Tissues, 
with and without BIO.D2 Anti-A 
Tram  LLBiz~ tissue* 
Tumor 
Tumor 
None 
Thymus 
Thymus 
None 
Embryo 
Embryo 
None 
Antiserum 
per mouse 
None 
0.3 ml. 
None 
None 
0.3 ml. 
None 
None 
0.3mL 
None 
Interval 
to assay 
days 
7 
7 
5 
5 
8 
8 
Mean tumor weight  (I0 mice) at different lympho- 
cyte dose levels  (in millions) 
12 
gm. 
.88 
>8 
.59 
.22 
.57 
6 
gm. 
1.23 
8 
.08 
.01 
.39 
3  1.5  0.75  0.38 
gm,  gm.  gm.  &m. 
.02  .27  .78  .66 
• 74  .79  1.13 
1.56 
4  2  1  0.5 
.19  .48  .43  .65 
.68  .90  .84 
.74  .63 
0  .12  .06  .31 
.36  .44 
.68 
Assays performed in (A ×  BI0.D2)F~ mice, each mouse receiving 1 million cells SaLA 
mixed with various lymphocyte dilutions. Tumors weighed at 7 (immunization with embryo 
or thymus) or 8 (immunization with tumor) days. Tumor weights set in bold face  are regarded 
as indicative of inhibition. 
* Tumor (SaI-A), 3 million cells per mouse; thymus, 15 million ceils per mouse; embryo 
given by trocar. 
repetition of this experiment gave essentially identical results except that there 
was not less than an 8-fold difference• Embryo given by trocar produced a par- 
ticularly strong immunity; activity was found at the one million cell level for 
unenhanced mice; it appeared in this experiment also in the enhanced mice at 
the maximum dose level, 13.9 million cells per mouse. The difference in activity 
is 14-fold. 
The selection of intervals of 7, 5, and 8 days for node assay after stimulation 
with tumor, thymus, and embryo respectively was based on earlier, published 
data on homograft immunity  (8, 16),  on pilot assays following immunization 
with thymus, and on determinations of the cell yield of draining lymph nodes 300  DEPRESSION OF IM.~ITNE RESPONSE TO HO~OGRAFTS 
obtained at different intervals after a  subcutaneous injection of foreign strain 
thymus. For the last named series of observations we are indebted to Mr. Meyer 
Gottlieb. 
Effect of Interval between Immunization and Node Assay.--Mitchison (8) found 
that the draining nodes of mice immunized with a tumor homograft could trans- 
fer immunity if removed at 5 or 10 days after the tumor graft, but not if re- 
moved at 3, 15, or 20 days. In the experiments described in the preceding sec- 
tion, we used intervals of 5, 7, and 8 days. Two experiments were also performed 
in which a much wider range of intervals was used. 
Unenhanced and passively enhanced mice were immunized with SaI-A, subcutaneously 
on the right side, at intervals of 3~, 4, 6, 9, 14, and 22 days prior to assay of the draining 
nodes. The assay was performed in strain B10.D2. Mice were killed at 1 week and the tumors 
weighed. The results are presented in Table II and Fig. 3. Besides the mean tumor weight, 
there is given, as a decimal in parentheses, the proportion of mice in each assay group with 
a detectable tumor; the number 1 means that 10 out of 10 mice had a tumor. 
Because SaI-A is incompatible with the B10.D2 mice used for the assay, tu- 
mors were smaller than in the experiments in which the assay was performed in 
hybrids.  (Current work shows that larger tumors can be obtained with larger 
tumor doses.) However, immunity was demonstrable with fewer node cells, pre- 
sumably because none of the cells was diverted from the tumor by an A com- 
ponent in the tissues of the host. The mean weights of tumors in 7 control groups 
were 0.24, 0.28, 0.07, 0.11, 0.31, 0.13 and 0.19 gm. The two low values of 0.07 
and 0.11 obtained in Experiment 1 in the normal lymphocyte control, are per- 
haps partly accounted for by the fact that these groups of mice were inoculated 
towards the end of a long experiment; the tumor preparation was 7 or 8 hours 
old.  However,  other groups done late in  the  same experiment were of more 
nearly typical size. As indicative of immunity in the node cells,  a mean tumor 
weight of 0.05 gin. or less was selected. Again the selection was somewhat arbi- 
trary. These inhibited groups always included a  number of entirely negative 
mice; the proportion with tumor was never greater than 0.6, and was 0  in 17 
cases, indicating complete inhibition. Only 1 group failed to fall in the sequence 
expected for a titer test. Among the 10 mice receiving 8 million cells each of 4- 
day nodes, there were 9 negatives and one mouse with a  tumor weighing 0.56 
gin. This gave a mean tumor weight of 0.06 gin. and hence above the level se- 
lected as indicative of inhibition.  Mice receiving the same node suspension at 
the 4 million and 2 million cell levels were all negative. 
In plotting the points in Fig. 3, it was usually possible to interpolate (by in- 
spection; no mathematical treatment  was  attempted)  between  two  adjacent 
lymph node dilutions, one of which produced and one of which did not produce, 
a reduction of mean tumor weight to 0.05 gm. or less. In a few cases the end- 
point fell outside the range of dilutions used; e.g., in Experiment 2, assay with 
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node cells. This point in the figure is placed above 0.25 but its exact position is 
obviously indeterminate. 
TABLE II 
Assay of Draining Nodes of BIO.D2 M~e That Received SaI-A, 3½, 4, 6, 9, 14,  or 22 Days 
Predously, with (Enhanced) or without (Unenhanced) BIO.DZ Anti-A 
Mean tumor weight (I0 mice), and (in parenthesis)  proportion of mice with 
tumor, at different lymphocyte dose levels gin millions)  Treatment  Experi- 
and inter~ a'l  ment 
to assay  No. 
4  2  1  0.5  0.25 
days 
Unenhanced 
3½ 
4 
6 
6 
9 
9 
14 
22 
Enhanced 
3½ 
4 
6 
6 
9 
9 
14 
22 
~onlrol A 
~outrol B 
11.7-6.3 
gfn•  gm. 
.08 (.7) 
o  (o) 
o  (o) 
gm. 
.o6 (.i) 
• 19 (1) 
.13 (.9) 
.05 (.4) 
.OS  (.5) 
.00 (. 1) 
.01 (.2) 
.05 (.2) 
o  (o) 
o  (o) 
.27 (1) 
• 19  (1) 
.10 (.9) 
.31 (1) 
.05 (.3) 
.03 (.3) 
.19 (.8) 
o  (o) 
.18  (i) 
o  (o) 
o  (o) 
o  (o) 
o  (o) 
o  (o) 
.01  (.2) 
o  (o) 
.18  (1) 
.21  (.9) 
.o8  (.8) 
.26  (•9) 
.05  (.s) 
.13  (1) 
.13  (.6) 
.04  (.3) 
•  24* (I) 
.o7~  (.7) 
.31  (1) 
.13  (.8) 
gm. 
•  19 (I) 
.O8 (.4) 
0  (0) 
0  (0) 
0  (0) 
0  (0) 
.06 (.5) 
.01 (.  I) 
.27 (I) 
.22 (1) 
.18 (.9) 
.39 (I) 
.18  (I) 
.07 (.7) 
.27 (.9) 
.25 (.9) 
.28 (1) 
.11 (.8) 
.19 (.9) 
gm. 
.24 (1) 
.14 (.9) 
.00 (. 1) 
.01 (.1) 
.08 (.3) 
o  (o) 
.25 (.8) 
.13 (.6) 
.12 (.7) 
.27 (1) 
gm. 
0  (o) 
.O4(.6) 
.o4 (.6) 
.lS (.8) 
.17 (.9) 
.22 (.9) 
Assay performed  in B10.D2's,  each  mouse receiving  million cells SaI-A mixed with 
various lymphocyte dilutions. Mice killed and tumors weighed at 7 days. Mean tumor weights 
of 0.05 gin. or less are regarded as indicative of inhibition and are set in bold face. Control A: 
normal node control; Control B: control receiving tumor only without node cells. 
* 3  million lymphocytes. 
3.4  million  lymphocytes. 
Several points of interest  are apparent from the table and the figure. First, 
while this sensitive assay revealed immunity in the node cells of enhanced mice 
at 6, 9, 14, and 22 days after tumor implantation, but not at 3~  or 4 days, the 
level was always lower than in unenhanced  mice• The difference  was greatest 
at 6 days; here there was about a 24-fold difference in Experiment  1 and more 
than a 32-fold difference in Experiment 2. The difference thereafter became pro- 302  DEPRESSION OF IMMUNE I~SPONSE TO  HOMOG1L~TS 
gressively less. Second, these experiments show that immunity can be detected 
over a  longer interval than was found by Mitchison (8).  In the unenhanced 
group, there was no immunity demonstrable in the nodes removed at 3~.~ days, 
but there was immunity at 4, 6, 9, 14, and 22 days. Third, in both experiments 
the unenhanced group showed a peak at 6 days, the enhanced group at 9 days. 
Fourth, in both groups there is a low point at 14 days and a subsequent rise at 
22 days. Since only one of the two experiments was extended beyond 9 days, 
this rise may be due to chance fluctuations. If real, it is perhaps related to the 
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mice at different  intervals  alter the implantation  of SaI given  with and without accompanying 
antiserum. 
second immune peak at about 24 days demonstrated by Barrett and Hansen 
(17).  The enhanced mice of course had large tumors at 22 days whereas the 
tumors in the unenhanced mice, after temporary growth, had disappeared. 
Number of Cells from Stimulated Nodes.--In the experiments described in the 
two preceding sections, the brachial, axillary, and inguinal lymph nodes from 
groups of 10 mice, variously treated, were placed in the cytosieve, the "lympho- 
cytes" extracted, and a cell count made. This makes it possible to calculate the 
"cells per side per mouse." The values are given in Table III. (This includes 2 
experiments not included in previous tables.) It will be seen that in general the 
lowest counts are given by the control nodes (range: 3,600,000 to 9,800,000),  the 
next highest by the nodes of enhanced and immunized mice (range: 7,900,000 
to 34,600,000), and the highest by unenhanced and immunized mice (range: 12,- O. D. SNELL, H..]'. WINN, J. H. STIMPI~LING,  AND S. J. PARKER  303 
000,000 to 41,800,000). All the very high counts, including some as early as 3~ 
days,  were obtained  from nodes  stimulated  by tumor.  Since many,  perhaps 
most, tumors carry viruses (18), this may account for the excessive cellular re- 
sponse in these instances. In the experiments in which normal tissue was used 
for immunization, the order of increasing cell yield was, without exception, con- 
trol, enhanced and immunized, and unenhanced and immunized. Thus the cells 
TABLE III 
Number of Cells Ex~raaed from Draining Lymph Nodes of BIO.D2 Mice Iraraunized wi~h 
Strain A Tissue, with (Enhanced) and without (Unenhanced) BIO.D2 Anti-A 
Immunization 
Interval 
Tissue  Sides  Dose/side 
Thymus 
~c 
Embryo 
Tumor 
Average 
Tumor 
~c 
c~ 
c¢ 
Both 
c* 
cc 
at 
*c 
Right 
c~ 
cc 
c4 
~c 
~c 
63 million 
15  " 
15  " 
Trocar 
3 million 
3 million 
3  " 
3  " 
3  " 
3  " 
3  " 
3  " 
3  " 
day* 
5 
5 
5 
8 
7 
4 
3½ 
6 
6 
9 
9 
14 
22 
Lymphocyte yield, celh/eide/ 
mouse  (m millions) 
Unen- 
Control  Enhanced  hanced 
3.6  12.6  13.6 
5.9  7.9  15.5 
9.1  13.8  14.6 
9.2  12.7  20.5 
3.9  9.7  12.6 
6.3 
9.1 
9.8 
11.3  15.4 
24.7  29.7 
21.0  14.9 
20.8  24.5 
26.2  22.6 
34.6  41.8 
19.6  43.4 
22.7  24.0 
12.3  12.0 
are not only proportionally more ~mmune in the unenhanced mice, but there are 
more of them. 
Passive Enhancement and Spleen Weights.--Green  (19)  has noted that  the 
splenic enlargement, normally present in rats bearing a transplantable tumor, is 
absent or only mildly present in rats which have received enhancing tissue in- 
jections  prior  to  the  tumor  implant.  In  one  of  our  experiments  in  which 
B10.D2's, with and without passive enhancement, were implanted with SaI-A, 
and killed  7  days later,  spleen  weights were determined.  The mean  weights 
were:  untreated  control,  0.081  gin.;  antiserum  and SaI-A, 0.115  gm.; SaI-A 
without antiserum, 0.153 gin. The differences are significant (P <  0.01). This 
confirms Green's observation. However, in a  comparable experiment in which 304  DEPRESSION  OF  IM~IUNE  RESPONSE  TO ttOMOGRAFTS 
the immunizing injection consisted of 15 million thymus cells, and the interval 
to killing was 5 days, the weights were: untreated, 0.090 gin.; antiserum and 
thymus, 0.113 gin.; thymus alone, 0.080 gin. Since the thymus and the thymo- 
cyte have special properties which might influence the spleen in one way or an- 
other (20, 21), these results do not necessarily contradict results obtained with 
tumors. 
The Effect of Passive Enhancement on the Formation of Humoral Isoantibody.-- 
The preceding experiments have shown that passive enhancement reduces the 
level of cellular immunity developed in the lymph nodes draining an implant of 
foreign tissue. Does passive enhancement likewise lower the humoral response 
to foreign tissue? This question was answered in the affirmative by two experi- 
ments. 
In  each  experiment,  36  B10.D2  mice  were  used.  Twenty-four  were  injected  intra- 
abdominally with  strain  A  tissue.  Twelve of  these,  and  the  12  otherwise untreated,  also 
received intraabdomlnally  0.3  cc.  B10.D2  anti-A.  In the first experiment,  each mouse re- 
ceived 61 million cells, mixed A  thymus  and spleen, in the second, 35 million cells of A thy- 
mus. Pairs of mice, usually a male and a female, were bled from the tail at 3, 6, 9, 12, 15, and 
18 days after the injections, and the serum of each mouse stored individually in a deep freeze. 
Each mouse was bled only once. All antisera in each experiment were titered on the same 
day against the same pool of strain A erythrocytes. The results are shown in Fig. 4, in which 
each point represents the geometric mean titer for two mice. 
As expected, the titer of the serum from mice receiving antiserum alone fell 
off progressively as the interval to bleeding increased. The curve for mice re- 
ceiving injections  of both antiserum and A tissue was surprisingly  similar. In 
the first experiment, the curve showed a rise above the controls at 6 days, prob- 
ably indicating antibody formation, but thereafter was below the controls;  in 
the second experiment  it was below the controls till the last day. Evidently in 
the presence of antiserum, the injected antigen induced only limited antibody 
formation. In the absence of passively transferred antiserum, on the contrary, 
the antigen stimulated a generous outpouring of antibody; in the first experi- 
ment the titer reached 1 in 10,240 at 9 days and in the second experiment,  1 in 
20,480 at 12 days. 
It should be noted that while isoantiserum  is cytotoxic to spleen cells, it is 
apparently not cytotoxic to mouse thymus cells (9). The passively transferred 
antiserum may have modified the antigen in the first experiment  through the 
destruction of that portion of the A cells which came from the spleen, but it 
should not have produced this type of modification in the second experiment. It 
is also noteworthy that in these experiments  the "blocking" effect of antibody 
was obtained when antigen was injected intraabdominally rather than by the 
usual subcutaneous  route. 
Kaliss  (5)  has reported  that when C57BL/Ks mice are given SaI, bled  at 
varying intervals,  and the serum tested for enhancing activity, the peak comes G. D.  Slq'ELL,  H.  ].  WIN'N, ]. H.  STIMPlCLING,  AND S. ]. PARKER  305 
at 21 days. Probably the tardiness of this peak results from the prolonged stim- 
ulus provided by a  tumor homograft. 
The Effect of Varying the Dose and the Kind of Immunizing Tissue.--The pre- 
ceding experiments have shown that while passive enhancement reduces both 
the cellular and humoral response to foreign tissue, it does not eliminate them 
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Fxo. 4. Graph showing the level of humoral antibody in BI0.D2 mice  at different  intervals 
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.shown. 
entirely. Whatever the nature of the "block" that antiserum erects, some anti- 
gen breaks through it. We have not investigated in detail the conditions that 
favor a bypassing of the antiserum block, but some evidence has been obtained 
that both the dose and the kind of tissue are important. 
Table IV shows the results of an experiment in which different doses of strain 
A thymus were given to BI0.D2's, with and without passive enhancement, fol- 
lowed by an assay at 7 days of the draining nodes in strain A mice. Serial dilu- 
tions were not used; nodes from each group of I0 BI0.D2's were pooled and the 306  DEPRESSION OP TMMUNE RESPONSE TO  HOMOGRA~'TS 
cell suspension assayed undiluted in 10 A's. There was tumor growth in all mice, 
but immune activity in some groups was indicated by a reduction in mean tu- 
mor size as compared with the controls. 
As expected, the activity of the nodes from the enhanced mice was less than 
the activity of the nodes from the unenhanced mice. The point of interest here 
is the effect of dosage. Strain A  thymus given at  the rate of 1 donor per  10 
B10.D2 recipients, or of 1 donor per 2 recipients, did not produce a detectable 
level of immunity in the enhanced mice. However, the nodes from the enhanced 
group receiving 2 thymuses each reduced the mean tumor weight from the con- 
TABLE IV 
lramun~y Induced by Various  Doses of A  Thymus in Draining Nodes of BIO.D2 Hosts, with 
and without Passive Enhancement 
A thymus, donors:host 
2:1 
1:2 
1:10 
None 
Enhanced* 
Mean weight 
gm. 
0.75 
1.36 
1.45 
Results of assay 
P~ 
<0.02 
0.5 
0.5 
Unenhanced 
Mean weight 
gm. 
0.63 
0.31 
1.00 
1.44 
P~ 
<0.01 
<0.01 
0.10 
B10.D2's killed and nodes assayed 7 days after injection of thymus. Nodes from each group 
of B10.D2 mice (10 mice in a group) pooled, and assayed, without serial dilutions, in  10 
strain A mice. Tumor dosage  for assay: 5,000 cells SaI-A per strain A mouse. Tumors removed 
and weighed at 19 days. 
* 0.5 ml. B10.D2 anti-A given intraperitoneally; thymus given about  1 hour  later sub- 
cutaneously on the right flank. 
:~ Significance of difference as compared with controls. 
trol value of 1.44 gin. to 0.75 gm. The difference is probably significant  (P < 
0.02). A large dose of tissue thus seemed to partly overcome the block imposed 
by the antiserum. 
We have previously reported (11)  that the addition of minced, normal strain 
A lymph nodes to SaI-A prior to implantation in actively enhanced mice will 
partly overcome the effect of the enhancement. This was tested by growth of 
the tumor implant, not by a node assay. The A node ceils, in this case acting as 
antigen, are apparently able to break through  the block imposed by the anti- 
serum and to induce at least some degree of cellular immunity. As a result there 
is reduced  tumor growth as compared with actively enhanced mice receiving 
either tumor alone or tumor plus isologous nodes. We have now repeated this 
experiment under a variety of conditions, including the use of other lymphoid O. D. SNELL, H. J'. VCINN, J. H. STIMPJFLING,  Alq'D  S. J. PARKER  307 
,tissues, and found it usually present though quite variable in degree. It has not 
been seen in passively enhanced mice, at least at the dose levels used in this par- 
ticular type of experiment. The difference between passively and actively en- 
hanced mice is perhaps not surprising, since in passively enhanced mice the 
tumor and nodes constitute a  primary stimulus, whereas in actively enhanced 
mice they are a secondary stimulus. 
In a few experiments this phenomenon was checked by a node assay. In one 
test, the draining nodes of groups of 10 or 20 actively enhanced B10.D2's receiv- 
ing SaI-A mixed with either B10.D2 (isologous) or A (homologous) nodes, were 
assayed at 3, 5, and 7 days in A mice. Mean tumor weights for the two groups 
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FIo. 5. Diagram showing the method used to estimate the level of cellular immunity in 
B10.D2 mice given an immunizing injection of strain A tissue, with B10.D2 anti-A either 
simultaneously  or subsequently. 
were, respectively, 0.72 gin. and 0.70 gin. at 3 days, 0.63 gin. and 0.21 gin. at 5 
days, 0.10 gin. and 0.02 tim. at 7 days. Where A nodes were added to the original 
tumor inoculum, the assay weights were less, indicating that the added A tissue 
was effective, despite enhancement of the hosts, in stimulating immunity. The 
effect was negligible at 3 days, but very clear at 5 days. In another, somewhat 
similar experiment, there was no significant difference at 7 days. 
The Effect of Antiserum  Given after a Homografl.--Kaliss  has reported that 
enhanced growth of SaI can be produced in C57BL/Ks mice by the injection of 
C57BL/Ks anti-A after as well as before or at the time of tumor implantation 
(4, 22). When the antiserum was given 2 days after SaI, all mice succumbed to 
the tumor; as the interval was increased beyond 2 days, the effect decreased  , but 
some enhancement was still obtained at 10 days.  Enhancement was absent at 
14 days. 
If the role of antiserum in enhancing tumor growth is accomplished through a 308  DEPRESSION  OF  IMMUNE  RESPONSE  TO  HOMOGRAFTS 
"blocking" or depression of cellular immunity, it follows from the above that a 
block or depression can be initiated after the administration of antigen. The di- 
rect test of this assumption would be a node assay performed on mice given an- 
tigen first and antiserum afterward. As of the present, the only tests we have 
performed are of a technically simpler and somewhat less conclusive nature. The 
plan of the experiments is shown in Fig. 5. 
B10.D2 mice were given 10 million celh each of strain A thymus subcutaneously, and either 
on the same day (day 0), or on day 1, 5, or 6, an injection of B10.D2 anti-A intraperitoneally. 
On day 7 they were given SaI-A, and another injection of B10.D2 anti-A. The pooled results 
of 3 experiments are shown in Table V. The first two and the last lines are control groups. 
Of 33 mice receiving tumor alone, 3, or 9 per cent, succumbed; of 29 mice receiving tumor and 
TABLE  V 
Blockage by Antiserum  of the Protective (Immunizing)  Effect of Strain A  Thymus in  BIO.D2 
Hosts, as Tested by a Subsequent Transplant of Strain A  Tumor SaI-A 
Strain A 
thymus, cells/ 
mouse, day 0* 
,N~O  ne 
None 
[0 million 
10  " 
lO  " 
10  " 
10  " 
B10.D2 anti-A, intraperitoneaUy, mlJmouse 
Day 0 
m 
0or 0.3 
0.3 
Day 1 
D 
0.3 
Day 5 
0.3 
Day 6 
m 
0.3 
Day 7 
0.3 or 0.2 
0.2 
0.2 
0.2 
0.2 
0.2  or 0.3 
Sal-Acells/ 
mouse, day 7* 
3  million 
3  " 
3  " 
3  " 
3  " 
3  " 
3  " 
Per cent dying 
(No. of mice in 
parentheses) 
9  (33) 
100 (29) 
67 (30) 
79 (29) 
40 (lo) 
30 (lo) 
3 (29) 
* Given subcutaneously on the right flank. 
antiserum (passive enhancement), all succumbed. When A thymus was given 1 week before 
tumor and antiserum, an effective (presumably cellular) immunity was induced which over- 
rode the enhancing treatment given with the tumor; only 1 of 29 mice succumbed. The re- 
maining 4 groups test the effect of antiserum given with or after the immunizing injection of 
thymus. The per cent deaths were 67, 79, 40, and 30 for antiserum given on days 0, 1, 5, and 
6.  By this test, antiserum was at least as effective in blocking the immunity (presumably 
cellular) induced by foreign tissue when given 1 day after the tissue as when given on the 
same day as the tissue. It was also effective to a limited extent on days 5 and 6, even though 
the test of immunity (SaI implant) was given on day 7, allowing an interval of only 1 or 2 
days for the antiserum to produce its effect. It may be noted that nodes assayed by the method 
of Winn on day 5 after an injection of thymus (15 million cells) show an appreciable level of 
immunity (Table I), probably quite sufficient to inhibit the growth of some millions of tumor 
cells when the two types of cells are mixed and implanted together, and immunity has also 
been found on day 4. Why, we may ask, does the injection of antiserum after this high tevel 
of immunity has been reached, result in the growth of SaI in at least some of the mice sub- 
sequently implanted therewith? While we cannot give a  conclusive answer to this question 
at the present time, the following would seem to provide a  plausible interpretation of this 
type of result. G. D. SNELL, H. J'. WINN, J. H.  STIMP~LING, AND S. J'. PARKER  309 
Following the injection of A  thymus into B10.D2 recipients, the immune mechanism of 
the recipients is set in motion, and beginning on day 3 or 4  there is a  generous and  active 
production of immune lymphocytes. This reaches a peak in the draining nodes on about day 
5, but in the absence of antiserum would continue at a  high level in these nodes and in the 
spleen (unpublished data) for some days longer. This production is terminated abruptly by 
the injection of antiserum. The immune lymphocytes as they are released from the nodes and 
spleen then have two targets to attack, first, the 10 million strain A thymus cells which con- 
stituted the immunizing injection and many of which are probably still distributed through 
the tissues of the host, and second, the 3 million tumor cells which were administered on day 
7. Much of their energy is diverted from the tumor, a diversion that would not occur if the 
nodes were removed for assay. When operating in vivo, also, the immune cells must move from 
the nodes or spleen to the tumor, a small target in comparison with the total body mass. In 
the in vitro test, the cells are directly mixed with the target. These three factors, the termina- 
tion by antiserum of the immune process, the diversion of immune cells from the tumor by 
the remnants of the immunizing tissue, and the need of searching out the target, are suffcient 
to account for the occasional progressive tumor growth that occurs under conditions in which 
an in vitro test would show sufficient immunity in the sum total of the lymphoid tissues to 
muse regular inhibition. 
DISCUSSION 
This paper is concerned with two hypotheses that have been proposed to ex- 
plain why antiserum causes enhanced growth of tumor homografts in certain 
tumor-host combinations. According to the first hypothesis (4),  the antiserum 
modifies the tumor, according to  the second (11),  it in some way blocks the de- 
velopment of cellular immunity (which is the kind of immunity necessary for 
the destruction of most homografts) in  the draining lymph nodes and other 
lymphoid organs, thereby permitting the tumor to grow. 
Kaliss (4) has reviewed the evidence for the first hypothesis. Several investi- 
gators (4, 23, 24) have observed improved growth, usually limited in extent, when 
tumors are retransplanted from mice that have been actively or passively en- 
hanced. In testing this hypothesis, we obtained negative results; tumors homo- 
grafted from thenative strain grew just as well, on the average, as tumors homo- 
grafted from enhanced mice. The fact that modification of the tumor is not a 
consistent phenomenon throws considerable doubt on the modification hypothe- 
sis. However, it is pertinent to consider why alteration, or apparent alteration, 
does sometimes occur. 
Tumors are complex, biological entities, and changes, fluctuating or perma- 
nent, due to a variety of causes, are possible. However, there is a very simple 
possible explanation of the effect of successful passage through a mouse of for- 
eign strain that should be eliminated before more indirect explanations are in- 
voked. This may be briefly stated as follows. An A tumor grown in A's usually 
contains a considerable population of strain A leukocytes. Leukocytes are par- 
ticularly rich in isoantigens  (3,  and  Winn, unpublished data),  and  they are 
mobile cells which tend to leave the site of a graft and enter the lymphatic circu- 
lation from which they can reach the lymph nodes or spleen. They are thus par- 310  DEPRESSION OF TM'MUN~ RESPONSE TO  HOMOGRA~TS 
ticularly effective, as antigen, in evoking homograft immunity (3, 11, 16). When 
the same tumor is passed through a foreign strain, its population of leukocytes 
becomes that of the foreign strain. SaI-A grown in enhanced B10.D2's acquires 
a  B10.D2 leukocyte population.  This tumor will evoke a  lower immunity in 
B10.D2's than a tumor taken directly from A's, and if the possibility for growth 
is close to a  threshold  for this particular tumor-host combination,  some pro- 
gressive growth may be expected. Some evidence pertinent to the role of lymph- 
oid cells as antigen is presented in the section of this paper dealing with the effect 
of varying the dose and the kind of immunizing tissue. One of a number of other 
unpublished experiments is pertinent and may be cited. SaI-A, with and without 
added A thymus, was transplanted in B10.D2's.  The SaI-A without added A 
thymus gave palpable  tumors which reached a size of ~  to 1 cm. in diameter 
and then regressed. The SaI-A with added thymus gave tiny tumors in 3 out of 
10 mice, none in the others. This illustrates the effect of added lymphoid ceils 
isologous with the graft. Experiments  from other laboratories,  which we have 
reviewed elsewhere (3), indicate that removal of lymphocytes from a graft will 
increase its chance of survival. Passage of a tumor through enhanced mice of a 
foreign strain is a simple method of accomplishing this removal, or at least the 
removal of lymphoid cells with the antigens necessary for inciting a homograft 
reaction in the particular foreign strain. 
The observation  of Ka]iss (4) that small pieces of SaI (solid form) immersed 
overnight in appropriate media show enhanced growth in C57BL/Ks can be ex- 
plained in the same way. Lymphoid ceils are relatively mobile, and would tend 
to migrate from the graft. This would reduce  the immunizing  potential of the 
graft. 
This effect of lymphoid ceils as antigen is not necessarily the correct explana- 
tion of the results under discussion, but at least it should be ruled out before 
more complex explanations are invoked. 
A way in which an anti-tumor antiserum might change the growth character- 
istics of a tumor is through changing its bacterial or viral flora. Many, perhaps 
most, tumors carry viruses as passengers.  There are reports of using antisera to 
eliminate these. In general, passenger viruses depress the growth potential of a 
tumor (18), so treatment with an antiserum might improve its growth. Such im- 
provement would be irrelevant to the enhancing phenomenon. 
Evidence presented in this paper shows that the administration of antiserum 
to B10.D2 mice regularly and consistently lowers the level of immunity which 
the mice develop following a homograft.  B10.D2 anti-A given  simultaneously 
with an SaI-A homograft depressed the cellular immunity in the draining nodes 
at 6 days after tumor implantation to 1/24th that of the controls in one experi- 
ment, and to less than 1/32nd that of the controls in another. ~he difference 
was present,  though somewhat less, at several other intervals tested. The ira- G. D.  SNELL,  H.  ~'. WINN~  ~. H.  STIMPI~LING~  AND S. J. PARKER  311 
munizing stimulus need not be tumor; the same sort of depressing effect of anti- 
serum on cellular immunity  was found when the immunizing tissue was strain A 
thymus or embryo. The production of humoral antibody was also partly blocked 
by injected antibody, and so was the increased cell yield from draining nodes 
and the increased spleen weight which are normal consequences of a homograft. 
Since cellular immunity is responsible for the rejection of SaI and most other 
non-leukotic  homografts,  the effect of antiserum on this type of immunity is 
quite sufficient to explain the enhancing phenomenon.  It also accounts for the 
fact that successful enhancement of normal tissue grafts has sometimes been 
achieved  (see reviews in references 3 and 4). It should be emphasized that the 
"blockage" produced by antiserum is not complete; in particular a rather high 
level of celhflar immunity was found 9 days after an SaI homotransplant to 
enhanced B10.D2's.  A complex balance between antibody, cellular immunity, 
and the nature and current state of a particular homograft must determine its 
eventual outcome. 
It remains to be determined where the "block" set up by the antiserum oc- 
curs. At least three possibilities must be considered. (a) The antiserum may pre- 
vent, or partially prevent, the antigen from reaching the regional nodes. An ap- 
parent obstacle to this hypothesis is that antiserum is effective when given after 
the homograft. This may not be as serious an objection as at first appears. This 
effect can be explained if we assume that cellular immunity develops only so 
long as antigen is feeding into the nodes, (or spleen), and terminates abruptly 
when the stimulus terminates. Hurnoral antibody production would presumably 
continue for a much greater interval, and this would be favorable to enhance- 
ment. We must also assume, when the graft is a normal tissue such as thymus, 
that a deposit remains for some time at the implantation site and, in the absence 
of antiserum, continues to feed antigen into the nodes. A variant of this alterna- 
tive would be the assumption that, in the presence of antibody, the antigen 
does not reach the lymph nodes, or does not reach them in effective form, be- 
cause antibody is able to accomplish the destruction or degradation of phago- 
cytized isoantigens.  (b) The antigen may reach the nodes in combination with 
antibody and in this form may provide an ineffective stimulus.  Published evi- 
dence on antigen-antibody complexes might be cited either for or against this 
hypothesis. (c) The block may be of some more central and as yet entirely unde- 
termined nature. It would be premature to attempt a choice between these hy- 
potheses. 
Finally, this study emphasizes the potency and importance of specifically im- 
mune cells in the homograft reaction. It seems probable that both immune and 
non-immune cells accumulate in and around a homograft. Antibody, by touch- 
ing off an "alarm" system, might actually accelerate the accumulation of non- 
immune cells. Histiocytes, presumably non-lmmune,  are present early and in 312  DEPRESSION  OF  IMMUNE  RESPONSE  TO ttOMOGRAFTS 
large numbers in enhanced mice bearing certain tumors (25).  Destruction of the 
graft presumably depends on the development and arrival of immune cells. This 
is blocked by the enhancing treatments. 
SUMMARY 
This paper reports tests of two hypotheses that have been proposed to  ac- 
count for the enhanced growth of tumor homografts in the presence of antiserum 
reactive with the graft (immunological enhancement). According to  the first 
hypothesis, enhancement is due to some "physiological" alteration in the tu- 
mor, induced by its contact with antiserum, which insures its survival despite 
the hostile response of the host. According to the second hypothesis, antiserum 
alters the response of the host. By blocking the development of the cellular type 
of immunity, which is the main agent in graft destruction, it permits the graft 
to survive. 
To test hypothesis 1, strain A tumor SaI was passed from A's, and from en- 
hanced B10.D2's, into untreated B10.D2's. The per cent of deaths was essen- 
tially the same in both groups (48 and 44 per cent, respective]y); there was no 
evidence that passage through enhanced B10.D2's altered the capacity of the 
tumor to grow in the foreign strain. Several other groups of mice included in the 
experiment all confirmed this conclusion. The experiment failed to confirm hy- 
pothesis 1. 
In the tests of hypothesis 2, the effect of isoantiserum on immune responses 
of both the humoral and cellular type was measured. When antiserum was given 
together with foreign strain lymphoid cells (antigen), almost no additional anti- 
body was manufactured; in contrast with this, controls receiving foreign cells 
only produced red cell agglutinating antibody in high titer. 
The effect of antiserum on the development of immunity of the cellular type 
was tested by the method of Winn. In this assay, presumptively immune node 
cells, in various dilutions, are mixed with tumor cells and injected into appro- 
priate mice. Immunity is indicated by inhibited tumor growth. Antiserum given 
at the same time as a tumor homograft greatly depressed the immunity of the 
cells expressed from the draining nodes. At 6 days after the graft, the level of 
immunity of cells from treated mice was 1/24th to 1/32nd that of cells from con- 
trols receiving tumor alone. The same sort of depressing effect was noted when 
the immunizing tissue was foreign thymus or embryo. Antiserum given 1 or more 
days after the immunizing tissue also resulted in a  lower level of cellular im- 
munity (but the assay used in this case was a less critical one). 
These results provide an adequate explanation of the phenomenon of im- 
munological enhancement, at least as it occurs in the particular test system used 
in these experiments. Since it is cellular immunity rather than humoral antibody 
that inhibits the growth of most grafts (transplantab.~e  leukemias are an excep- G. D. SNELL, H  ~"  WINN, J. H. STIMPI~LING,  AND S. J. PARKER  313 
tion), the depression of this immunity by antibody is favorable to the growth of 
a homograft. 
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